NOT-DA-23-015: Notice of Early Expiration and Reissue of RFA-DA-22-038, "Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)"

Notice of Early Expiration and Reissue of RFA-DA-22-038, "Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)"

Notice Number:

NOT-DA-23-015

Key Dates

Release Date:

January 13, 2023

Related Announcements

RFA-DA-22-038 - Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to alert applicants of the early termination of RFA-DA-22-038 "Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)". The request for applications, RFA-DA-22-038, will be terminated, effective immediately. No further applications will be accepted for consideration under this FOA.

A new RFA to support "Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)" will be issued to correct review criteria. Applications for the new RFA will be due beginning on March 7, 2023.

Applicants are encouraged to consider applying to the new FOA (expected to be published in February 2023): RFA-DA-24-037, "Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)".

Inquiries

Please direct all inquiries to:

Marsha F. Lopez, Ph.D., M.H.S.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6504
Email: [email protected]